Starpharma Holdings Ltd. reached a substantial outlicensing agreement with Genentech, valued at over $569 million, lifting Starpharma’s stock by 73%. The deal grants Genentech access to Starpharma’s dendrimer-enhanced drug delivery technology, a platform designed to improve therapeutic payload delivery and efficacy. This partnership is expected to accelerate the development of new medicines supported by the dendrimer platform, underscoring growing industry interest in advanced drug delivery systems to overcome formulation challenges and enhance clinical outcomes.